ବାରିସିଟିନିବ

ବାରିସିଟିନିବ
Clinical data
Trade names	Olumiant, others
Synonyms	INCB28050, LY3009104
AHFS/Drugs.com	monograph
MedlinePlus	a618033
data	EU EMA: yes; US DailyMed: Baricitinib;
Pregnancy; category	AU: D ; Use is contraindicated;
Routes of; administration	By mouth (tablets)
Legal status
Legal status	AU: S4 (Prescription only) ; US: ℞-only ; EU: Rx-only ; ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	79%
Protein binding	50%
Metabolism	CYP3A4 (<10%)
Elimination half-life	12.5 hours
Excretion	75% urine, 20% faeces
Identifiers
	IUPAC name 2-[1-Ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile;
ECHA InfoCard	100.219.080
Chemical and physical data
Formula	C16H17N7O2S
Molar mass	୩୭୧.୪୨ g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCS(=O)(=O)N1CC(C1)(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3;
	InChI InChI=1S/C16H17N7O2S/c1-2-26(24,25)22-9-16(10-22,4-5-17)23-8-12(7-21-23)14-13-3-6-18-15(13)20-11-19-14/h3,6-8,11H,2,4,9-10H2,1H3,(H,18,19,20); Key:XUZMWHLSFXCVMG-UHFFFAOYSA-N;

ବାରିସିଟିନିବ, ଅନ୍ୟମାନଙ୍କ ମଧ୍ୟରେ ଏକ ବେପାର ନାମ ଓଲୁମିଆଣ୍ଟ, ଏକ ଔଷଧ ଯାହା ରିମାଟଏଡ୍ ଆର୍ଥ୍ରାଇଟିସ୍ (RA) ଏବଂ କୋଭିଡ-୧୯ (COVID-19)ର ଚିକିତ୍ସା ପାଇଁ ବ୍ୟବହୃତ ହୁଏ । ^[୫] ^[୬] ରିମାଟଏଡ୍ ଆର୍ଥ୍ରାଇଟିସରେ ଏହା ବ୍ୟବହୃତ ହୁଏ ଯେତେବେଳେ ଏହା ନେକ୍ରୋସିସ୍ ଫ୍ୟାକ୍ଟର୍ (TNF) ଇନହିବିଟରଦ୍ୱାରା ନିୟନ୍ତ୍ରିତ ହୁଏନି । ^[୫] କୋଭିଡ-୧୯ର ଗୁରୁତର ରୋଗରେ ବ୍ୟବହୃତ ହୁଏ । ^[୬] ଏହା ପାଟିରେ ଦିଆଯାଏ । ^[୪]

ସାଧାରଣ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ବାନ୍ତି, ଉପର ଶ୍ୱାସନଳୀ ସଂକ୍ରମଣ, ହର୍ପିସ ଜୋସ୍ଟର, ଏବଂ ହର୍ପିସ୍ ସିମ୍ପଲେକ୍ସ ହୋଇପାରେ । ^[୭] ଅନ୍ୟାନ୍ୟ ପାର୍ଶ୍ୱ ପ୍ରତିକ୍ରିୟାରେ ଭୟଙ୍କର ସଂକ୍ରମଣ, ଲିମ୍ଫୋମା, ରକ୍ତ ଜମାଟ ବାନ୍ଧିବା, ଜଠରାନ୍ତ୍ର ଛିଦ୍ର, ଏବଂ ଯକୃତ ସମସ୍ୟା ଅନ୍ତର୍ଭୁକ୍ତ ହୋଇପାରେ । ^[୭] ଗର୍ଭାବସ୍ଥାରେ ବ୍ୟବହାର କରୁଥିବା କୌଣସି ତଥ୍ୟ ନାହିଁ, ଯଦିଓ ଅନ୍ୟ ପ୍ରାଣୀମାନଙ୍କରେ ବ୍ୟବହାର ଶିଶୁର କ୍ଷତି କରିପାରେ । ^[୭] ଏହା ଜାନୁସ୍ କିନାସେ (JAK)ର ଏକ ପ୍ରତିରୋଧକ, ଜେଏକେ୧ ଏବଂ ଜେଏକେ୨ ଉପ ପ୍ରକାରକୁ ଅବରୋଧ କରିଥାଏ । ^[୮]

୨୦୧୭ ମସିହାରେ ୟୁରୋପରେ ଏବଂ ୨୦୧୮ରେ ଆମେରିକାରେ ଡାକ୍ତରୀ ବ୍ୟବହାର ପାଇଁ ଅନୁମୋଦିତ ହୋଇଥିଲା । ^[୪] ^[୫] ଯୁକ୍ତରାଜ୍ୟରେ ୨ ମିଗ୍ରାର ୨୮ ବଟିକାର ମୂଲ୍ୟ ୨୦୨୧ରେ ୮୦୦ ପାଉଣ୍ଡ ଥିଲା । ^[୯] ଯୁକ୍ତରାଷ୍ଟ୍ରରେ ଏହି ରାଶିର ମୂଲ୍ୟ ପ୍ରାୟ ୨,୩୦୦ ଡଲାର ଥିଲା । ^[୧୦]

ଆଧାର ସମ୍ପାଦନା

↑ ^୧.୦ ^୧.୧ "Olumiant Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 20 September 2021. Retrieved 12 June 2021.
↑ "Baricitinib (Olumiant) Use During Pregnancy". Drugs.com. 8 November 2019. Archived from the original on 26 June 2020. Retrieved 16 March 2020.
↑ "AusPAR: Baricitinib". Therapeutic Goods Administration (TGA). 20 May 2021. Archived from the original on 20 May 2021. Retrieved 11 June 2021.
↑ ^୪.୦ ^୪.୧ ^୪.୨ "Olumiant EPAR". European Medicines Agency (EMA). 3 December 2019. Archived from the original on 25 August 2021. Retrieved 1 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
↑ ^୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Olumiant- baricitinib tablet, film coated". DailyMed. 13 November 2019. Archived from the original on 27 September 2020. Retrieved 16 March 2020.
↑ ^୬.୦ ^୬.୧ "Hospitalized Adults: Therapeutic Management". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 9 January 2022. Retrieved 8 January 2022.
↑ ^୭.୦ ^୭.୧ ^୭.୨ "Baricitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 September 2021. Retrieved 8 January 2022.
↑ "Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. Archived from the original (PDF) on 15 March 2018. Retrieved 1 September 2021.
↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1153. ISBN 978-0857114105.
↑ "Olumiant Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 January 2021. Retrieved 8 January 2022.

[Olumiant_AU_PI-1] ୧.୦ ^୧.୧ "Olumiant Product Information" (PDF). Therapeutic Goods Administration (TGA). Archived from the original on 20 September 2021. Retrieved 12 June 2021.

[Drugs.com_pregnancy-2] "Baricitinib (Olumiant) Use During Pregnancy". Drugs.com. 8 November 2019. Archived from the original on 26 June 2020. Retrieved 16 March 2020.

[3] "AusPAR: Baricitinib". Therapeutic Goods Administration (TGA). 20 May 2021. Archived from the original on 20 May 2021. Retrieved 11 June 2021.

[EPAR2022-4] ୪.୦ ^୪.୧ ^୪.୨ "Olumiant EPAR". European Medicines Agency (EMA). 3 December 2019. Archived from the original on 25 August 2021. Retrieved 1 September 2021. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[PI2022-5] ୫.୦ ^୫.୧ ^୫.୨ ^୫.୩ "Olumiant- baricitinib tablet, film coated". DailyMed. 13 November 2019. Archived from the original on 27 September 2020. Retrieved 16 March 2020.

[NIH2022Cov-6] ୬.୦ ^୬.୧ "Hospitalized Adults: Therapeutic Management". COVID-19 Treatment Guidelines (in ଇଂରାଜୀ). Archived from the original on 9 January 2022. Retrieved 8 January 2022.

[AHFS2022-7] ୭.୦ ^୭.୧ ^୭.୨ "Baricitinib Monograph for Professionals". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 21 September 2021. Retrieved 8 January 2022.

[CHMP2022-8] "Summary of opinion for Olumiant" (PDF). European Medicines Agency (EMA). 15 December 2016. Archived from the original (PDF) on 15 March 2018. Retrieved 1 September 2021.

[BNF81-9] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 1153. ISBN 978-0857114105.

[10] "Olumiant Prices, Coupons & Patient Assistance Programs". Drugs.com (in ଇଂରାଜୀ). Archived from the original on 22 January 2021. Retrieved 8 January 2022.

[୫]

[୬]

[୪]

[୧]

[୨]

[୩]

[୭]

[୮]

[୯]

[୧୦]